Stealth BioTherapeutics Corp. ADS
MITO
MITO was delisted on the 15th of November, 2022.
7 hedge funds and large institutions have $2.69M invested in Stealth BioTherapeutics Corp. ADS in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
14% less capital invested
Capital invested by funds: $3.11M → $2.69M (-$425K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$2.25M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$47.4K |
| 3 |
Morgan Stanley
New York
|
+$10.2K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.36K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$133 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$167K |
| 2 |
Millennium Management
New York
|
-$95.8K |
| 3 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$7K |
MITO Hedge Fund Activity: Q3 2019 in Review
7 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Stealth BioTherapeutics Corp. ADS (MITO) for Q3 2019, worth a combined $2.69M — down 14% from $3.11M a quarter earlier.
Fund positioning in MITO was balanced in Q3 2019: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Kingdon Capital Management, adding an estimated $2.25M. The largest seller was Bank of America, cutting an estimated $167K.
- 7 institutional investors held Stealth BioTherapeutics Corp. ADS (MITO) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $2.69M of Stealth BioTherapeutics Corp. ADS stock for Q3 2019, down 14% quarter-over-quarter.
- 1 fund opened new Stealth BioTherapeutics Corp. ADS positions in Q3 2019 and 1 closed out, a net change of 0 holders.
- The largest Stealth BioTherapeutics Corp. ADS buyer in Q3 2019 was Kingdon Capital Management, an estimated $2.25M added.
- The largest Stealth BioTherapeutics Corp. ADS seller in Q3 2019 was Bank of America, an estimated $167K sold.
Based on aggregated 13F filings for Q3 2019.